Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Oncology Therapeutics Inc (BBOT)

Bridgebio Oncology Therapeutics Inc (BBOT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,095,049
  • Shares Outstanding, K 79,989
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,275 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta 0.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.49
  • Number of Estimates 5
  • High Estimate -0.43
  • Low Estimate -0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.68 +28.18%
on 12/03/25
14.78 -7.37%
on 12/05/25
+1.29 (+10.40%)
since 11/05/25
3-Month
9.50 +44.11%
on 09/15/25
14.78 -7.37%
on 12/05/25
+3.79 (+38.28%)
since 09/05/25
52-Week
8.50 +61.06%
on 08/05/25
14.78 -7.37%
on 12/05/25
+3.24 (+31.00%)
since 12/03/24

Most Recent Stories

More News
BBOT to Participate in Upcoming December Investor Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,...

BBOT : 13.69 (+18.63%)
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations...

BBOT : 13.69 (+18.63%)
BBOT to Participate in the Jefferies Global Healthcare Conference in London

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,...

BBOT : 13.69 (+18.63%)
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,...

BBOT : 13.69 (+18.63%)
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing...

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolism Robust monotherapy activity, as well as combination...

BBOT : 13.69 (+18.63%)
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,...

BBOT : 13.69 (+18.63%)
Leerink Partners Sticks to Its Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

In a report released on September 29, Andrew Berens from Leerink Partners maintained a Buy rating on BridgeBio Oncology Therapeutics. The company’s shares closed yesterday at $12.44.Elevate Your Investing...

BBOT : 13.69 (+18.63%)
BBOT to Participate in Upcoming September Investor Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies,...

BBOT : 13.69 (+18.63%)
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025  Closed concurrent...

BBOT : 13.69 (+18.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K' malignancies. BridgeBio Oncology Therapeutics, formerly known as Helix Acquisition Corp. II, is based in SOUTH SAN FRANCISCO....

See More

Key Turning Points

3rd Resistance Point 17.90
2nd Resistance Point 16.34
1st Resistance Point 15.01
Last Price 13.69
1st Support Level 12.13
2nd Support Level 10.57
3rd Support Level 9.25

See More

52-Week High 14.78
Last Price 13.69
Fibonacci 61.8% 12.38
Fibonacci 50% 11.64
Fibonacci 38.2% 10.90
52-Week Low 8.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar